Has Joyce Peterson received payments from drug or device companies?

Yes. Drug and device makers reported $4,861 in general payments to Joyce Peterson across 261 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Joyce Peterson did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Joyce Peterson come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Joyce Peterson

Adult Health · Slidell, LANPI 1588005128

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.1% of the total across 261 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 12.6% — the pattern of someone who eats at a lot of different presentations.

$4,861in general payments, 2019–2025

Across 261 payments — averaging $18.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$610
Otsuka America Pharmaceutical, Inc.$457
Amgen$394
Calliditas Therapeutics US Inc.$388
Mallinckrodt Hospital Products Inc.$379
Vifor Pharma, Inc.$364
plus $2K from 18 others

What the payments were for

Food & beverage$4,62495%
Education$2375%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca(2 entities)	33	$610
Otsuka America Pharmaceutical, Inc.	27	$457
Amgen(2 entities)	23	$394
Calliditas Therapeutics US Inc.	16	$388
Mallinckrodt Hospital Products Inc.	18	$379
Vifor Pharma, Inc.	20	$364
Fresenius USA Marketing, Inc.	19	$345
Akebia Therapeutics Inc	18	$338
OPKO Pharmaceuticals, LLC	19	$335
Bayer	15	$248
Aurinia Pharma U.S., Inc.	11	$207
Novartis	6	$175
Travere Therapeutics, Inc.	13	$159
Novo Nordisk	6	$135
Ardelyx, Inc.	3	$75
Cormedix Inc.	2	$41
Lilly USA, LLC	2	$40
Apellis Pharmaceuticals, Inc.	2	$36
Ultragenyx Pharmaceutical Inc.	2	$31
Daiichi Sankyo Inc.	1	$24
GSK	2	$24
Scpharmaceuticals Inc.	1	$20
Otsuka Pharmaceutical Development & Commercialization, Inc.	1	$18
Boehringer Ingelheim	1	$16

How this compares

$4,861 in reported general payments places this provider in the 75th percentile of 203 adult health providers in Louisiana.

See all adult health providers in Louisiana →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
XphozahTenapanor Hcl	51	$145,303
VelphoroSucroferric Oxyhydroxide	16	$42,985
VeltassaPatiromer Calcium Sorbitex	30	$29,303
Sevelamer Carbonate	107	$16,177
LokelmaSodium Zirconium Cyclosilicate	12	$8,136
Calcium Acetate	63	$5,964
Midodrine Hcl	77	$2,889
Hydralazine Hcl	57	$355
Nifedipine ErNifedipine	14	$335
Ondansetron OdtOndansetron	30	$185
Lidocaine-PrilocaineLidocaine/Prilocaine	16	$182
Furosemide	34	$137
Gabapentin	13	$122
Trazodone Hcl	15	$72
Losartan Potassium	26	$67

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro	$345	$42,98516 claims
AstraZenecaLokelma	$610	$8,13612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 203 adult health providers in Louisiana.